Genome-Based Bacterial Vaccines: Current State and Future Outlook
- 16 April 2013
- journal article
- review article
- Published by Springer Nature in BioDrugs
- Vol. 27 (5) , 419-430
Abstract
Genome-based reverse vaccinology (RV) is a multi-step experimental strategy which starts from in silico analysis of whole genome sequences, from which vaccine candidates can be selected by using bioinformatic algorithms to identify putative protective antigens. In this review, we examine the current state of genome-based RV-engineered vaccines and future applications. The first product of genome-based RV is Bexsero®, a vaccine developed for preventing Neisseria meningitidis serogroup B infection, and the strategy is currently being used for the development of new vaccines for other obdurate and emerging bacterial diseases. Improved sequencing technologies and the ongoing whole-genome sequence analyses of helminths, protozoa, and ectoparasites also currently serve as a basis for an RV strategy to produce new potential vaccines against eukaryotic pathogens. We also highlight an emerging approach—structure-based vaccinology—that exploits the information derived from the determined three-dimensional structures of vaccine candidates. Regardless, genome-based RV and other vaccine discovery platforms still depend on empirical experimental science to glean, from the hundreds of identified antigens from any one pathogen, those that should be combined to produce an effective vaccine.Keywords
This publication has 113 references indexed in Scilit:
- The genomes of four tapeworm species reveal adaptations to parasitismNature, 2013
- The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigensVaccine, 2012
- Next generation pneumococcal vaccinesCurrent Opinion in Immunology, 2011
- Rational antibody-based HIV-1 vaccine design: current approaches and future directionsCurrent Opinion in Immunology, 2010
- Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coliProceedings of the National Academy of Sciences, 2010
- Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humansProceedings of the National Academy of Sciences, 2010
- Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimatesThe Lancet, 2009
- Global epidemiology of meningococcal diseaseVaccine, 2009
- A universal vaccine for serogroup B meningococcusProceedings of the National Academy of Sciences, 2006
- The genome of Cryptosporidium hominisNature, 2004